Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 13/20 | 0.83 |
| ▸ | PFKFB4 | Q16877 | 11/20 | 0.83 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787986 | 0.91 | PFKFB3 (1.00) | PFKFB3PFKFB4CMA1 | |
| SCHEMBL788429 | 0.88 | PFKFB3 (0.87) | PFKFB3PFKFB4CMA1 | |
| SCHEMBL787883 | 0.88 | PFKFB3 (0.69) | PFKFB3PFKFB4LMNASMN1; SMN2CMA1 | |
| SCHEMBL787998 | 0.86 | PFKFB3 (0.80) | PFKFB3PFKFB4CMA1 | |
| SCHEMBL788484 | 0.83 | PFKFB3 (0.63) | PFKFB3PFKFB4LMNASMN1; SMN2CMA1 | |
| SCHEMBL788058 | 0.82 | PFKFB3 (1.00) | PFKFB3PFKFB4CMA1 | |
| SCHEMBL15063686 | 0.81 | PFKFB3 (0.60) | PFKFB3PFKFB4LMNASMN1; SMN2 | |
| SCHEMBL788791 | 0.80 | PFKFB3 (0.90) | PFKFB3PFKFB4CMA1 | |
| SCHEMBL794845 | 0.80 | PFKFB3 (0.78) | PFKFB3PFKFB4CMA1 | |
| SCHEMBL2236072 | 0.80 | LMNA (0.75) | LMNASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616450-B1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2018-05-02 | — | — | EP | disclosed |
| EP-2616450-B1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2018-05-02 | — | — | EP | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| EP-2616450-A2 | SULFONAMIDE COMPOUNDS | Kancera AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | SULT1A1, STS, ARSA | PFKFB3 952/4885PFKFB4 889/4885LMNA 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.